| Li, Xiaoying |
| Completed | 4 | 328 | RoW | Intensive lifestyle intervention, Dapagliflozin 10 MG Oral Tablet, Placebo Oral Tablet | Shanghai Zhongshan Hospital | Type 2 Diabetes | 01/23 | 01/23 | | |
| Completed | 4 | 19 | RoW | Dihydroartemisinin | Shanghai Zhongshan Hospital | Polycystic Ovary Syndrome | 03/23 | 04/23 | | |
| Completed | 4 | 310 | RoW | Caffeine Citrate 20 MG/1 ML Intravenous Solution [CAFCIT] | Children's Hospital of Chongqing Medical University | Apnea of Prematurity, Caffeine, Weaning Oxygen, Medicine Regimen | 10/23 | 10/23 | | |
| Recruiting | 4 | 70 | RoW | Canagliflozin 100mg or Sitagliptin 100mg | Shanghai Zhongshan Hospital | Type 2 Diabetes, Cardiovascular Diseases, Cardiac Perfusion Defect | 12/24 | 03/25 | | |
NCT04605861: The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight Patients |
|
|
| Completed | 3 | 414 | RoW | Liraglutide, Placebo | Shanghai Zhongshan Hospital | Obese, Overweight | 12/22 | 04/23 | | |
NCT05816057: A Study of the Efficacy and Safety of Semaglutide Injection in the Treatment of Type 2 Diabetes Mellitus |
|
|
| Completed | 3 | 476 | RoW | semaglutide injection | Hangzhou Jiuyuan Gene Engineering Co. Ltd., | Diabetes Mellitus, Type 2 | 07/23 | 10/23 | | |
SURMOUNT-OSA, NCT05412004: Obstructive Sleep Apnea Master Protocol GPIF: A Study of Tirzepatide (LY3298176) in Participants With Obstructive Sleep Apnea |
|
|
| Completed | 3 | 469 | Europe, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Sleep Apnea, Obesity | 03/24 | 03/24 | | |
NCT05834868: Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 2 Diabetes |
|
|
| Recruiting | 3 | 805 | RoW | THDB0206 Injection, Insulin Lispro Injection | Tonghua Dongbao Pharmaceutical Co.,Ltd | Type 2 Diabetes | 03/24 | 10/24 | | |
NCT06396429: To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese |
|
|
| Recruiting | 3 | 540 | RoW | HRS9531 injection, Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity | 07/25 | 08/25 | | |
NCT05680129: A Phase 3 Study to Evaluate the Efficacy of XW003 Compared With Dulaglutide in Participants With T2DM |
|
|
| Active, not recruiting | 3 | 623 | RoW | Ecnoglutide high dosage, XW003, Ecnoglutide low dosage, Dulaglutide, Metformin | Hangzhou Sciwind Biosciences Co., Ltd. | T2DM, Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT05702073: To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin. |
|
|
| Recruiting | 3 | 400 | RoW | INS068 injection, Insulin Glargine | Jiangsu HengRui Medicine Co., Ltd. | Type 2 Diabetes Mellitus | 10/24 | 10/24 | | |
NCT06287437: HRS9531 Controls Weight Regain in Obese Subjects |
|
|
| Active, not recruiting | 2 | 72 | RoW | HRS9531, HRS9531 placebo | Shanghai Zhongshan Hospital | Obesity | 06/25 | 12/25 | | |
NCT05881837: Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes |
|
|
| Active, not recruiting | 2 | 249 | RoW | HRS9531 injection, HRS9531 injection Placebo | Fujian Shengdi Pharmaceutical Co., Ltd. | Overweight or Obesity | 10/24 | 10/24 | | |
NCT06417099: Efficacy of Dihydroartemisinin for Treating PCOS |
|
|
| Recruiting | 2 | 30 | RoW | Dihydroartemisinin | Shanghai Zhongshan Hospital | Polycystic Ovary Syndrome | 03/25 | 05/25 | | |
| Not yet recruiting | 2 | 180 | NA | HDM1002 100 mg QD, HDM1002, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks, Placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Overweight and Obesity | 10/24 | 11/24 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT05516966: Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Patients With Type 2 Diabetes Mellitus |
|
|
| Completed | 1 | 64 | RoW | HRS9531, Placebo, Dulaglutide Injection | Fujian Shengdi Pharmaceutical Co., Ltd. | Diabetes Mellitus, Type 2 | 05/23 | 05/23 | | |
NCT06520540: HDM1002 Tablets in Chinese Overweight and Obese Adult Subjects |
|
|
| Not yet recruiting | 1 | 72 | RoW | HDM1002 100 mg QD 12weeks, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks，Q 2W for titration, HDM1002 400 mg QD 12weeks，Q 3W for titration, Placebo | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Glucagon-Like Peptide-1 Receptor Agonists | 11/24 | 12/24 | | |
NCT06652009: Radical Radiotherapy Versus Radical Surgery for UTUC |
|
|
| Recruiting | N/A | 60 | RoW | Radical nephroureterectomy, Radical radiotherapy | Peking University First Hospital | Renal Pelvis Cancer | 12/26 | 12/29 | | |
NCT06598761: Postoperative Adjuvant Immunotherapy Combined with Radiotherapy Versus Surgery Alone in Locally Advanced UTUC |
|
|
| Recruiting | N/A | 60 | RoW | Immunotherapy+radiotherapy, surveillance alone | Peking University First Hospital | Ureter Cancer, Renal Pelvic Carcinoma, Advanced Urothelial Carcinoma | 12/26 | 08/27 | | |
NCT06652022: Radiotherapy Combined with Systemic Therapy Versus Systemic Therapy for Oligometastatic UTUCs |
|
|
| Recruiting | N/A | 102 | RoW | Systematic therapy combined with radiotherapy, Systematic drug treatment | Peking University First Hospital | Oligometastatic Disease, Ureter Cancer, Renal Pelvic Carcinoma | 12/26 | 12/29 | | |
NCT06427642: Efficacy Evaluation of UCB-MNCs in the Treatment of Refractory Neonatal Diseases |
|
|
| Recruiting | N/A | 120 | RoW | Mononuclear cells, Mild hypothermia therapy, Breathing support technique, Total parenteral nutrition | Shandong Qilu Stem Cells Engineering Co., Ltd., Qilu Children's Hospital of Shandong University | Hypoxic-Ischemic Encephalopathy, Bronchopulmonary Dysplasia, Short Bowel Syndrome | 05/24 | 04/25 | | |
| Completed | N/A | 149 | RoW | iNCDSS based insulin regime, routine insulin treatment regime | Shanghai Zhongshan Hospital, Shanghai Fifth People's Hospital,Fudan University, XuHui Central Hospital of Shanghai, Shanghai, China | Type 2 Diabetes | 09/22 | 09/22 | | |
NCT04898621: Dietary Fructose on Microbiota and Hepatosteatosis |
|
|
| Completed | N/A | 58 | RoW | 75g fructose solution, 150g fructose solution | Shanghai Zhongshan Hospital, Fudan University | Hepatic Steatosis, Dietary Fructose Exposure | 08/22 | 12/22 | | |
NCT05409391: Insulin Titration System Based on Deep Learning |
|
|
| Completed | N/A | 16 | RoW | Insulin Titration System | Shanghai Zhongshan Hospital | Diabetes Mellitus Type 2 - Insulin-Treated | 10/22 | 10/22 | | |
NCT06434584: Explainable Insulin Decision-making System to Assist Physicians in Diabetes Management |
|
|
| Completed | N/A | 48 | RoW | without AI assistance, with AI dosage assistance, with explainable AI assistance, with faulty explainable AI assistance | Shanghai Zhongshan Hospital | Diabetes | 03/23 | 06/23 | | |
| Recruiting | N/A | 190 | RoW | | Shanghai Zhongshan Hospital | Body-Weight Trajectory | 06/23 | 09/23 | | |
NCT06319300: Artificial Intelligence-assisted Insulin System in Type 2 Diabetes in General Wards |
|
|
| Recruiting | N/A | 140 | RoW | AI-assisted insulin dose adjustment model, the Artificial Intelligence-assisted Insulin Dose Adjustment System, doctor's insulin dose adjustment | Shanghai Zhongshan Hospital, Shanghai Fifth People's Hospital,Fudan University | Diabetes Type 2 | 03/26 | 05/26 | | |
NCT06434623: Federal Learning Algorithm for an Intelligent Insulin Decision System for Dynamic Glucose Control in Type 2 Diabetic Patients |
|
|
| Not yet recruiting | N/A | 30100 | NA | patient record | Shanghai Zhongshan Hospital | Diabetes | 06/26 | 06/26 | | |
NCT06120374: Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC |
|
|
| Recruiting | N/A | 178 | RoW | Radiotherapy, SBRT, Chemotherapy, Based on platinum and gemcitabine, Immunotherapy, Mainly on PD-1/PD-L1 | Peking University First Hospital | Urothelial Carcinoma | 06/27 | 06/29 | | |
GUARD, NCT05349955: Effects and Safety of Diabetic GUideline Algorithm Implementation Performed by Primary Care Physicians in the Community |
|
|
| Recruiting | N/A | 5600 | RoW | Intensive guideline algorithm implementation, Conventional guideline algorithm implementation | Shanghai Zhongshan Hospital | Type 2 Diabetes, Cardiovascular Complication, Diabetic Kidney Disease | 11/26 | 11/26 | | |
NCT04544527: The Risk Factors of Cardiovascular Disease in Elderly Diabetic Patients: A Prospective Cohort Study |
|
|
| Recruiting | N/A | 10000 | RoW | | Shanghai Zhongshan Hospital | Diabetes Mellitus, Cardiovascular Diseases, Complication Diabetic | 12/30 | 12/31 | | |
